IPO to Fund Nanoparticle Clinical Trials

March 11, 2014 | Cerulean Pharma is launching a $75 million IPO to fund clinical trials of its nanoparticle cancer-fighting technology. The timing isn't good though as some analysts predict a biotech sell-off. Boston Globe


Add Comment

Text Only 2000 character limit

Page 1 of 1

For reprints and/or copyright permission, please contact Angela Parsons, 781.972.5467.